EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Volmaran Fegal
Country: Zimbabwe
Language: English (Spanish)
Genre: Education
Published (Last): 19 January 2004
Pages: 110
PDF File Size: 18.17 Mb
ePub File Size: 6.9 Mb
ISBN: 482-6-14776-575-5
Downloads: 11638
Price: Free* [*Free Regsitration Required]
Uploader: Fenrijinn

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

EUFEST assesses the effectiveness of a low studu of haloperidol versus regular doses of 4 second generation antipsychotics: We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: Analysis was by intention to treat. We studu an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries.

Evid Based Ment Health. Psychopathology – positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2. Retention to allocated study drug, which is eufrst time that the patient stays on the randomised drug within the study dose range. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: Diagnosis of schizophrenia; 2.

  DESCARGAR GRATIS LIBRO CALCULO LEITHOLD PDF

At regular time intervals patients are followed-up until stufy months after recruitment: Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1. Such studies were usually conducted in highly selected samples, and were fufest designed and financed by the manufacturer of the drug tested.

Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Eligibility Participant inclusion criteria 1.

The primary outcome measure is retention in treatment, defined as time sudy discontinuation of study drug. Rationale and eugest of the trial. Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2.

Home Who are we? The Lancet ; Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Previous Trial Back to results Next Trial. Ethics approval received from the local medical ethics committee. Quality of life 6. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.

Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder? SchizophreniaSchizophreniform disorderSchizoaffective disorder.

  DATASHEET MAX1632 PDF

PfizerAstraZenecaSanofi-Aventis. Natural history of schizophrenia.

Patients and their treating physicians were not blinded to the assigned treatment. This outcome is assessed at regular time intervals until 12 months after recruitment.

Multicentre, randomised active controlled, parallel group trial. Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. The principal investigators are Prof. The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. Schizophreniform or schizoaffective disorder; 3. The primary outcome measure was all-cause treatment discontinuation.

The presence of one or more of the contra-indications against any of the study drugs. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance.

Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder.

These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics.